Stay updated with breaking news from End Results Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide ... | May 6, 2023
CHICAGO — Among those who survived early-onset colorectal cancer, approximately 16% developed a second cancer, with higher risk reported among men, according to a population-based study presented at Digestive Disease Week. “The number of cancer survivors is increasing and is projected to grow to 26 million by 2040 in the United States,” Aniruddha Rathod, PhD, MBBS, MPH, a
Watch Dr. Brandon Blue, from Moffitt Cancer Center, discuss health disparities during the CURE Educated Patient Multiple Myeloma Summit.
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet published detailed data from the...